Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo Therapeutics (NASDAQ:APVO) announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session and present at Cambridge Healthcare Institute's Pep Talk conference in January 2025. The presentation will showcase how Aptevo uses its ADAPTIR and ADAPTIR-FLEX platforms to accelerate cancer therapy development. Dr. Pavlik will demonstrate the company's modular biotherapeutic approach using clinical candidates Mipletamig and ALG.APV-527 as examples. The company currently has five compounds in clinical and preclinical development and plans to introduce a new molecule in early 2025.
Aptevo Therapeutics (NASDAQ:APVO) ha annunciato che Peter Pavlik, PhD, Direttore Senior di Ingegneria delle Proteine, presiederà una sessione e presenterà alla conferenza Pep Talk dell'Istituto di Salute di Cambridge nel gennaio 2025. La presentazione metterà in evidenza come Aptevo utilizza le sue piattaforme ADAPTIR e ADAPTIR-FLEX per accelerare lo sviluppo di terapie contro il cancro. Il Dr. Pavlik dimostrerà l'approccio modulare bioterapeutico dell'azienda utilizzando i candidati clinici Mipletamig e ALG.APV-527 come esempi. Attualmente, l'azienda ha cinque composti in fase di sviluppo clinico e preclinico e prevede di introdurre una nuova molecola all'inizio del 2025.
Aptevo Therapeutics (NASDAQ:APVO) anunció que Peter Pavlik, PhD, Director Senior de Ingeniería de Proteínas, presidirá una sesión y presentará en la conferencia Pep Talk del Instituto de Salud de Cambridge en enero de 2025. La presentación mostrará cómo Aptevo utiliza sus plataformas ADAPTIR y ADAPTIR-FLEX para acelerar el desarrollo de terapias contra el cáncer. El Dr. Pavlik demostrará el enfoque modular bioterapéutico de la empresa utilizando los candidatos clínicos Mipletamig y ALG.APV-527 como ejemplos. Actualmente, la empresa tiene cinco compuestos en desarrollo clínico y preclínico y planea introducir una nueva molécula a principios de 2025.
Aptevo Therapeutics (NASDAQ:APVO)은 2025년 1월 케임브리지 헬스케어 연구소의 Pep Talk 회의에서 세션을 주재하고 발표할 것이라고 발표했습니다. 이 발표에서는 Aptevo가 암 치료 개발을 가속화하기 위해 ADAPTIR 및 ADAPTIR-FLEX 플랫폼을 어떻게 활용하는지를 보여줄 것입니다. Pavlik 박사는 임상 후보 Mipletamig 및 ALG.APV-527을 예로 들어 회사의 모듈식 바이오 치료 접근 방식을 시연할 것입니다. 현재 회사는 임상 및 전임상 개발 중인 다섯 가지 화합물이 있으며, 2025년 초에 새로운 분자를 도입할 계획입니다.
Aptevo Therapeutics (NASDAQ:APVO) a annoncé que Peter Pavlik, PhD, Directeur Senior de l'Ingénierie des Protéines, présidera une session et présentera à la conférence Pep Talk de l'Institut de Santé de Cambridge en janvier 2025. La présentation démontrera comment Aptevo utilise ses plateformes ADAPTIR et ADAPTIR-FLEX pour accélérer le développement des thérapies contre le cancer. Dr. Pavlik illustrera l'approche biothérapeutique modulaire de l'entreprise en utilisant les candidats cliniques Mipletamig et ALG.APV-527 comme exemples. Actuellement, l'entreprise a cinq composés en développement clinique et préclinique et prévoit d'introduire une nouvelle molécule début 2025.
Aptevo Therapeutics (NASDAQ:APVO) gab bekannt, dass Peter Pavlik, PhD, Senior Director für Proteinengineering, eine Sitzung leiten und auf der Pep Talk-Konferenz des Cambridge Healthcare Institute im Januar 2025 präsentieren wird. Die Präsentation wird zeigen, wie Aptevo seine ADAPTIR und ADAPTIR-FLEX Plattformen nutzt, um die Entwicklung von Krebstherapien zu beschleunigen. Dr. Pavlik wird den modularen biotherapeutischen Ansatz des Unternehmens anhand der klinischen Kandidaten Mipletamig und ALG.APV-527 demonstrieren. Das Unternehmen hat derzeit fünf Verbindungen in der klinischen und präklinischen Entwicklung und plant, Anfang 2025 ein neues Molekül einzuführen.
- Company has five compounds in clinical and preclinical development pipeline
- New molecule introduction planned for early 2025
- None.
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform" at Cambridge Healthcare Institute's, Pep Talk 2025
SEATTLE, WASHINGTON / ACCESSWIRE / November 26, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, todayannounced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a "Bi and Multispecific Biologics" session and present a talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform," at the Cambridge Healthcare Institute's, Pep Talk conference, in January 2025.
The presentation will illustrate how Aptevo leverages its proprietary platforms to rapidly advance the development of innovative cancer therapies and use clinical candidates Mipletamig and ALG.APV-527 to exemplify proof of concept for its modular biotherapeutic approach, reducing risk and increasing the likelihood of clinical success for future drug candidates. Aptevo has five compounds in clinical and preclinical development and anticipates introducing a new molecule in early 2025.
This leadership opportunity underscores Aptevo's technology and its commitment to driving innovation in functional drug production, creating molecules that perform in the clinic the way they were designed to perform at inception.
"Therapeutic candidates are often talked about once they are in human trials, especially when positive results are generated. But the genesis of those drugs and the speed with which they are produced, serves as the backbone of all therapeutic innovation. We work to create molecules that will be safe and tolerable in humans and target cancers as directly and effectively as possible," said Dr. Pavlik. "My presentation will describe how employing modular biotherapeutics can drive pipeline productivity, a critical capability, especially for smaller biotechnology companies navigating a competitive landscape. More specifically, we will explore the power of Aptevo's ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, which enable the rapid development of novel multispecific biotherapeutics, accelerating the journey from drug discovery to clinical trials and ultimately patient benefit."
About Dr. Pavlik
Peter Pavlik, PhD, serves as the Senior Director of Protein Engineering at Aptevo Therapeutics. In his career at Aptevo and previously MedImmune/AstraZeneca and Los Alamos National Labs, he has implemented novel technologies to streamline discovery of binding domains and their incorporation into stable and efficacious biotherapeutics. Dr. Pavlik has oversight over all processes currently used at Aptevo which are optimized to multiple areas of drug development from target validation to antibody discovery to IND and to clinic. Peter has a unique understanding of the biopharma industry from the large and small company perspectives.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard of care venetoclax + azacitidine. Mipletamig has orphan status for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX®. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations regarding the effectiveness of its ADAPTIR® and ADAPTIR-FLEX® platform technologies and whether such technologies will accelerate drug discovery and development, statements related to the performance of Aptevo's drug candidates in the clinic and whether such performance will translate into improved patient outcomes, statements related to the progress of and enthusiasm for Aptevo's preclinical and clinical programs, statement related to Aptevo's expectation to add another targeted preclinical asset to the pipeline, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "believes," "expects," "potential," "designed," "engineered," "innovative," "initiate," "allow," "promise," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social, macroeconomic, and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation, enrollment and maintenance of patients in clinical trials, uncertainties inherent in the results of preliminary or interim data and preclinical and clinical studies being predictive of the results of later-stage clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine as well as the war between Israel and Hamas, and macroeconomic conditions such as rising inflation and interests rates, increased market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
Aptevo Therapeutics
Miriam Weber Miller
Email: IR@apvo.com or millerm@apvo.com
Phone: 206-859-6629
SOURCE: Aptevo Therapeutics
View the original press release on accesswire.com
FAQ
What will Aptevo Therapeutics (APVO) present at Pep Talk 2025?
How many compounds does Aptevo Therapeutics (APVO) have in development as of November 2024?
When is Aptevo Therapeutics (APVO) planning to introduce its next new molecule?
